M Lloyd Jones1, S Hummel, N Bansback, B Orr, M Seymour. Show Affiliations » 1. School of Health and Related Research, University of Sheffield, UK.
Abstract
Entities: Chemical Disease
Mesh: See more » Antimetabolites, Antineoplastic/adverse effectsAntimetabolites, Antineoplastic/therapeutic useAntineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useAntineoplastic Agents, Phytogenic/adverse effectsAntineoplastic Agents, Phytogenic/therapeutic useAntineoplastic Combined Chemotherapy Protocols/therapeutic useCamptothecin/adverse effectsCamptothecin/analogs & derivativesCamptothecin/therapeutic useColorectal Neoplasms/drug therapyColorectal Neoplasms/economicsColorectal Neoplasms/epidemiologyColorectal Neoplasms/mortalityCost-Benefit AnalysisDrug CostsEngland/epidemiologyHumansIrinotecanOrganoplatinum Compounds/adverse effectsOrganoplatinum Compounds/therapeutic useOxaliplatinQuality of LifeQuinazolines/adverse effectsQuinazolines/therapeutic useRandomized Controlled Trials as TopicSurvival AnalysisThiophenes/adverse effectsThiophenes/therapeutic useTreatment OutcomeWales/epidemiology
Substances: See more » Antimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Agents, PhytogenicOrganoplatinum CompoundsQuinazolinesThiophenesOxaliplatinIrinotecanraltitrexedCamptothecin
Year: 2001 PMID: 11990245
Source DB: PubMed Journal: Health Technol Assess ISSN: 1366-5278 Impact factor: 4.014